FDA approves Alzheimer’s drug donanemab after months of delay
The Food and Drug Administration gave approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing the progression of the devastating disease outweigh its risks, drugmaker Eli Lilly announced. The agency, in a surprise move in March, had delayed approval of the drug to further review its safety and effectiveness. … Read more